← back to search

Mathieu Bourdenx

National Hospital for Neurology and Neurosurgery · FR
Area of research
Neurology · Physiology
Research interest
Research interests include Parkinson's Disease Mechanisms and Treatments, Alzheimer's disease research and treatments, Autophagy in Disease and Therapy, and Neurological disorders and treatments.
h-index
28
citations
7,191
works
80
NIH funding
primary concept
Biology
email

Recent publications

OpenScientist: evaluating an open agentic AI co-scientist to accelerate biomedical discovery
medRxiv 2026cited by 0position: middledoi
Chaperone-mediated autophagy regulates neuronal activity by sex-specific remodelling of the synaptic proteome
Nature Cell Biology 2025cited by 10position: middledoi
VPS4A is the selective receptor for lipophagy in mice and humans
Molecular Cell 2024cited by 27position: middledoi
mTORC2–NDRG1–CDC42 axis couples fasting to mitochondrial fission
Nature Cell Biology 2023cited by 45position: middledoi
The different autophagy degradation pathways and neurodegeneration
Neuron 2022cited by 474position: middledoi
Chaperone-mediated autophagy prevents collapse of the neuronal metastable proteome
Cell 2021cited by 314position: firstdoi
Acetylated tau inhibits chaperone-mediated autophagy and promotes tau pathology propagation in mice
Nature Communications 2021cited by 212position: middledoi
Brain injections of glial cytoplasmic inclusions induce a multiple system atrophy-like pathology
Brain 2021cited by 24position: middledoi
Identification of distinct pathological signatures induced by patient-derived α-synuclein structures in nonhuman primates
Science Advances 2020cited by 59position: firstdoi
Identification of distinct pathological signatures induced by patient-derived α-synuclein structures in non-human primates
bioRxiv (Cold Spring Harbor Laboratory) 2019cited by 5position: firstdoi
Selective autophagy as a potential therapeutic target for neurodegenerative disorders
The Lancet Neurology 2018cited by 352position: middledoi
Rare variants in the neuronal ceroid lipofuscinosis gene MFSD8 are candidate risk factors for frontotemporal dementia
Acta Neuropathologica 2018cited by 40position: middledoi
Targeting α-synuclein for treatment of Parkinson's disease: mechanistic and therapeutic considerations
The Lancet Neurology 2015cited by 505position: middledoi
Pathophysiology of L-dopa-induced motor and non-motor complications in Parkinson's disease
Progress in Neurobiology 2015cited by 471position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

Ana María Cuervo · Montefiore Medical Center6 papers (2018–2025)Aurora Scrivo · Institut de Biomedicina de la Universitat de Barcelona4 papers (2018–2025)Antonio Díaz · Universidad de La Laguna3 papers (2018–2021)Rajat Singh · University of California, Los Angeles2 papers (2023–2024)Li Gan · Zhejiang Chinese Medical University2 papers (2021–2025)Enrique Luengo · Universidad Autónoma de Madrid2 papers (2021–2021)Wassilios G. Meissner · University of Otago2 papers (2015–2021)Mridul Sharma · University of California, Los Angeles2 papers (2023–2024) · 2 papers (2015–2021)Erwan Bézard · Centre National de la Recherche Scientifique2 papers (2015–2021)Nadia Storm · National Health Laboratory Service2 papers (2018–2021)José Antonio Rodríguez‐Navarro · Instituto Ramón y Cajal de Investigación Sanitaria2 papers (2021–2021)Adrián Martín‐Segura · Madrid Institute for Advanced Studies2 papers (2021–2022)Nuria Martínez-López · University of California, Los Angeles2 papers (2023–2024)Yves R. Juste · Albert Einstein College of Medicine2 papers (2021–2021)Laura Santambrogio · Cornell University2 papers (2021–2025)Miquel Vila · Universitat de Barcelona2 papers (2015–2021)Simone Sidoli · Albert Einstein College of Medicine2 papers (2023–2025)Susmita Kaushik · University of Pennsylvania2 papers (2021–2025)Inmaculada Tasset · Institute on Aging2 papers (2021–2025)